Modelling patient drug exposure profiles in vitro to narrow the valley of death

The current drug development pipeline is time-consuming, costly and inefficient. To better model interactions between pharmaceuticals and human physiology and, thus, increase the likelihood of drug success in clinical trials, the effect of pharmacokinetic drug profiles on cellular behaviour should be tested early in drug development.